A5028112952- Breast Cancer Treatment Studies
- Breast Lesions and Carcinomas
- Breast Implant and Reconstruction
- Lymphatic System and Diseases
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- BRCA gene mutations in cancer
- Reconstructive Surgery and Microvascular Techniques
- Systemic Sclerosis and Related Diseases
- Cancer Genomics and Diagnostics
- Cancer Diagnosis and Treatment
- Advanced Breast Cancer Therapies
- Cancer and Skin Lesions
- Brain Metastases and Treatment
- Cancer Cells and Metastasis
- Advanced Radiotherapy Techniques
- MRI in cancer diagnosis
- Salivary Gland Tumors Diagnosis and Treatment
- Global Cancer Incidence and Screening
- Head and Neck Cancer Studies
- Diagnosis and Treatment of Venous Diseases
- Endometrial and Cervical Cancer Treatments
- Body Image and Dysmorphia Studies
- Body Composition Measurement Techniques
- Cancer Risks and Factors
Memorial Sloan Kettering Cancer Center
2016-2025
Kettering University
2017-2024
Creative Commons
2023
Breast Center
2021
Biogipuzkoa Health Research Institute
2018-2019
American College of Surgeons
2017
Bryn Mawr Hospital
2010-2015
NewYork–Presbyterian Hospital
2008
Cornell University
2008
Prospective trials have demonstrated sentinel lymph node (SLN) false-negative rates of less than 10% when 3 or more SLNs are retrieved in patients with clinically node-positive breast cancer rendered node-negative neoadjuvant chemotherapy (NAC). However, nodal recurrence such treated SLN biopsy (SLNB) alone unknown because axillary dissection (ALND) was performed all patients, limiting adoption this approach.To evaluate a consecutive cohort (cN1) receiving NAC, followed by negative SLNB...
Importance Data on oncological outcomes after omission of axillary lymph node dissection (ALND) in patients with breast cancer that downstages from positive to negative neoadjuvant chemotherapy are sparse. Additionally, the best surgical staging technique this scenario is unknown. Objective To investigate sentinel biopsy (SLNB) dual-tracer mapping or targeted (TAD), which combines SLNB localization and retrieval clipped node. Design, Setting, Participants In multicenter retrospective cohort...
Objective: To determine rates of axillary dissection (ALND) and nodal recurrence in patients eligible for ACOSOG Z0011. Background: Z0011 demonstrated that with cT1-2N0 breast cancers 1 to 2 involved sentinel lymph nodes (SLNs) having breast-conserving therapy had no difference locoregional or survival after SLN biopsy alone ALND. The generalizability the results importance radiotherapy (RT) is unclear. Methods: Patients alone. Prospectively defined indications ALND were metastases ≥3 SLNs...
Risk factors for breast cancer-related lymphedema (BCRL) after axillary lymph node dissection (ALND) are poorly understood.To evaluate rates of and risk associated with BCRL in a prospective cohort women treated ALND.This screening study performed at tertiary cancer center enrolled 18 years older undergoing surgery unilateral ALND the primary setting or sentinel biopsy.Risk during first 2 radiotherapy.Patients were prospectively evaluated arm volume (perometer) measurements, was defined as...
Radioactive seed localization (RSL) has emerged as an alternative to wire (WL) in patients with nonpalpable breast cancer. Few studies have prospectively evaluated patient satisfaction and outcomes RSL. We report the results of a randomized trial comparing RSL WL our community hospital. enrolled 135 cancer between 2011 2014. Patients were or WL. rated pain convenience on 5-point Likert scale. Characteristics compared groups. Of enrolled, 10 excluded (benign pathology, palpable cancer,...
Abstract Background: Data on the oncologic safety of omission axillary lymph node dissection (ALND) in positive (N+) patients who downstage to ypN0 with neoadjuvant chemotherapy (NAC) is sparse. Additionally, there no consensus which staging procedure should be used this setting, sentinel biopsy (SLNB) alone or combination localization and retrieval clipped node, also known as targeted (TAD). Whether reduction false negative rate observed TAD translates into a significant recurrence unknown....
Breast cancer-related lymphedema (BCRL) is a common complication of axillary lymph node dissection (ALND) but can also develop after sentinel biopsy (SLNB). Several models have been developed to predict the risk disease development before and surgery; however, these shortcomings that include omission race, inclusion variables are not readily available patients, low sensitivity or specificity, lack assessment for patients treated with SLNB.
Abstract BRCA1 and BRCA2 pathogenic variant carriers develop breast cancers with distinct pathological characteristics mutational signatures that may result in differential response to chemotherapy. We compared rates of pathologic complete (pCR) after NAC between BRCA1/2 noncarriers a cohort 1426 women (92 [6.5%] 73 [5.1%] ) clinical stage I–III cancer treated followed by surgery from 11/2013 01/2022 at Memorial Sloan Kettering Cancer Center. The majority received...
The nodal burden of patients with residual isolated tumor cells (ITCs) in the sentinel lymph nodes (SLNs) after neoadjuvant chemotherapy (NAC) (ypN0i+) is unknown, and axillary management not standardized. We investigated rates additional positive (LNs) at node dissection (ALND) oncologic outcomes ypN0i+ treated without ALND.